Menu
ncarol.com
  • Home
  • Business
  • Finance
  • Financial
  • Music
  • Loans
  • Stocks
  • Boat Dealers
  • Yacht Buyer
ncarol.com

Substantial Funding, Debt Resolution, HOPE Dividend, Successful Clinical Trial Towards Accelerated Drug Approval for Bipolar Depression: Nasdaq: NRXP
ncarol.com/10269813

Trending...
  • Impact Futures Group expands through acquisition of specialist healthcare sector training provider Caring for Care
  • Still Searching for the Perfect Valentine's Gift? Lick Personal Oils Offers Romantic, Experience-Driven Alternatives to Traditional Presents
  • $10 Price Target in Think Equity Report Supported by Inventory Financing Floorplan Boot to $60 Million for 2026 Sales Growth in Pre-Owned Boats: $OTH
NASDAQ:NRXP NRXP 2 NRXP 3 NRXP 4 NRXP 5
HOPE Therapeutic Subsidiary Focused on Developing a Best-in-Class Network of Clinics for Patients with Suicidal Depression and Related Disorders. HOPE is Planned to be Spun Out as a Separate Company to be Owned by NRXP Shareholders, and New Investors. Effort to be Funded Apart from NRXP.

WILMINGTON, Del. - ncarol.com -- For more information on $NRXP visit: https://www.nrxpharma.com/ OR https://compasslivemedia.com/case-study/nrx-pharmaceuticals/

NRx Pharmaceuticals, Inc. (Stock Symbol: NRXP) is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. NRXP is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain.

NRXP has partnered with Alvogen Pharmaceuticals around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.

More on ncarol.com
  • Americans Need $1.26 Million to Retire But Have Just $38K Saved — So They're Building Income Instead
  • Does EMDR Really Work? New Article Explores How Trauma Gets Stuck in the Brain and How Healing Begins
  • New Medium Article Explores Why Emotional Conversations Fail and What Most People Don't Understand About Connection
  • Play-Based STEM Pilot in Daycares Achieve 100% Student Fun and Major Gains in Confidence & Curiosity
  • Cherokee Historical Association Moves to Co-Directorship, Names New Executive Leaders

NRXP is working on a New Drug Application for NRX-100 (IV ketamine) in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRXP was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.

HIGHLIGHTS

Developing Therapeutics for the Treatment of CNS Disorders, Specifically Suicidal Bipolar Depression, Chronic Pain and PTSD.

Company Funded For New Drug Applications (NDAs) for NRX-100 (ketamine) and NRX-101

Audit of HOPE Therapeutics Subsidiary Complete, SEC Filing of Spinout Planned for Current Quarter.

Secured $10.8 - $16.3 Million Convertible-Debt Funding from an Institutional Investor.

NRX-100 NDA for Suicidal Depression Based on Data from Four Clinical Trials in Nearly 1000 Participants Demonstrating Highly Significant Efficacy.

Ketamine Findings Confirmed in Published 43,000 Person Cohort Study.

More on ncarol.com
  • $80 Million Revenue Backlog for AI Cybersecurity Company Building the Future of Integrated Cybersecurity and Public Safety: $CYCU
  • The Brave and the Rescued Honors LA Fire Department First Responders
  • Slick Cash Loan shares credit score tips for borrowers using bad credit loans
  • Crossroads4Hope Welcomes New Trustees to Board of Directors as Organization Enters 25th Year of Caring
  • PromptBuilder.cc Launches AI Prompt Generator Optimized For ChatGPT, Gemini, Grok & Claude

Phase 2b/3 Trial Data Presented at the American Society of Clinical Psychopharmacology. Profile Demonstrates Possible Best in Class.

Plans to file New Drug Application for Accelerated Approval under Breakthrough Therapy Designation and Priority Review of NRX-101.

Stability Data Continues to Mature on Three Manufacturing Lots Required for the NRX-100 (IV ketamine) NDA filing.

Company Announced Alignment with FDA on its Pediatric Study Plan for NRX-100, Also a Requirement for Filing of NDA.

Media Contact

Company Name: NRx Pharmaceuticals, Inc.
Contact Person: Matthew Duffy, Chief Business Officer
Email: mduffy@nrxpharma.com
Phone: (484) 254-6134
Country: United States
Website: https://www.nrxpharma.com

DISCLAIMER: https://corporateads.com/disclaimer/

Disclosure listed on the CorporateAds website

Contact
Corporate Ads
***@frontpagestocks.com


Source: Corporate Ads
Filed Under: Business, Finance

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on ncarol.com
  • FeedSocially - Post Once, Publish Everywhere
  • James D. Harding Promoted to Century Fasteners Corp. – Managing Director
  • Finland's New Gambling Watchdog Handed Sweeping Powers to Revoke Licenses and Block Illegal Casino Sites
  • Powering the AI, Defense and Aerospace Future with Energy Infrastructure and Digital Asset Strength: KULR Technology Group, Inc. $KULR
  • $10 Price Target in Think Equity Report Supported by Inventory Financing Floorplan Boot to $60 Million for 2026 Sales Growth in Pre-Owned Boats: $OTH
  • Poolvillas Expands Local Presence on the Costa Blanca with New Offices in Moraira and Denia – Over 30 Years of Expertise Now Even Closer to Guests
  • Radarsign Redefines Crosswalk Safety with Launch of CrossCommand™ RRFB Crosswalk
  • OpenSSL Corporation Opens 2026 Advisory Committees' Elections: Shape the Future!
  • Steve Everett Jr. Named President of L.T. Hampel Corporation
  • Acuvance Acquires ROI Healthcare Solutions, Building a Dedicated Healthcare ERP Practice
  • Max Tucci Award-Winning Media Powerhouse Launches New Podcast —Executive Produced by Emmy-Winning Daytime Icons Suzanne Bass & Fran Brescia Coniglio
  • MILBERT.ai Brings Real Time Session Defense to Google Workspace and Google Cloud
  • PROXIMITY: An Invitational Exhibit of 10 North Carolina Artists
  • Appliance Outlet Caps Off a Record-Setting 2025 Nationwide, Gears Up for Even Greater Growth in 2026
  • HBA of Durham, Orange & Chatham Counties Announces 2025 Award Recipients & Installs 2026 Leadership
  • Home Prices Just Hit 5X Median Income — So Americans Are Buying Businesses Instead of Houses
  • CCHR White Paper Urges Government Crackdown on Troubled Teen and For-Profit Psychiatric Facilities
  • Still Searching for the Perfect Valentine's Gift? Lick Personal Oils Offers Romantic, Experience-Driven Alternatives to Traditional Presents
  • Boston Industrial Solutions' BPA Certified BX Series Raises the Bar for Pad Printing Inks
  • Boston Corporate Coach™ Sets Global Standard for Executive Chauffeur Services Across 680 Cities
_catLbl0 _catLbl1

Popular on ncarol.com

  • Walmart $WMT and COSTCO.COM $COST Distribution as SonicShieldX™ Platform Sets the Stage for Accelerated Growth in 2026: AXIL Brands (N Y S E: AXIL) - 117
  • $26 Billion Global Market by 2035 for Digital Assets Opens Major Potential for Currency Tech Company with ATM Expansion and Deployment Plans Underway - 112
  • UK Financial Ltd Announces CoinMarketCap Supply Verification And Market Positioning Review For Regulated Security Tokens SMPRA And SMCAT - 106
  • David Boland, Inc. Awarded $54.3M Construction Contract by U.S. Army Corps of Engineers, Savannah District - 101
  • Lick Personal Oils Introduces the Ultimate Valentine's Day Gift Collection for Romantic, Thoughtful Gifting
  • International Law Group Expands Emergency Immigration Consultations for Somali Minnesotans Amid ICE Actions
  • Phinge Founder & CEO Robert DeMaio Ranked #1 Globally on Crunchbase, Continues to Convert Previous Debt Owed to Him by Phinge into Convertible Notes
  • AI-Driven Drug Development with Publication of New Bioinformatics Whitepaper for BullFrog AI: $BFRG Strengthens Its Position in AI Drug Development
  • UK Financial Ltd Makes History as MayaCat (SMCAT) Becomes the World's First Exchange-Traded ERC-3643 Security Token
  • Robert DeMaio, Phinge Founder & CEO, Ranked #1 Globally on Crunchbase, Continues to Convert Previous Debt Owed to Him by Phinge into Convertible Notes

Similar on ncarol.com

  • Americans Need $1.26 Million to Retire But Have Just $38K Saved — So They're Building Income Instead
  • Does EMDR Really Work? New Article Explores How Trauma Gets Stuck in the Brain and How Healing Begins
  • New Medium Article Explores Why Emotional Conversations Fail and What Most People Don't Understand About Connection
  • $80 Million Revenue Backlog for AI Cybersecurity Company Building the Future of Integrated Cybersecurity and Public Safety: $CYCU
  • Slick Cash Loan shares credit score tips for borrowers using bad credit loans
  • Crossroads4Hope Welcomes New Trustees to Board of Directors as Organization Enters 25th Year of Caring
  • UK Financial Ltd Advances Compliance Strategy With January 30th CATEX Exchange Listing Of Maya Preferred PRA Preferred Class Regulated Security Token
  • NOW OPEN - New Single Family Home Community in Manalapan
  • Why 'Instant-Liquidity' Gaming is Dominating the Nordic Tech Demographic
  • Cyntexa Outlines a Principles-first Approach to Modern Enterprise Transformation
Copyright © 2026 ncarol.com | Contact Us | Privacy Policy | Terms of Service | Contribute